Search hospitals > Indiana > Indianapolis
Sidney and Lois Eskenazi Hospital
Claim this profileIndianapolis, Indiana 46202
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Human Immunodeficiency Virus Infection
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
218 reported clinical trials
21 medical researchers
Summary
Sidney and Lois Eskenazi Hospital is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Breast Cancer, Human Immunodeficiency Virus Infection, Lung Cancer, Colorectal Cancer and other specialties. Sidney and Lois Eskenazi Hospital is involved with conducting 218 clinical trials across 410 conditions. There are 21 research doctors associated with this hospital, such as Kathy Miller, MD, Nabil Adra, MD, Shadia Jalal, MD, and Greg Durm.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Kathy Miller, MDIU Health North Hospital8 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
17 reported clinical trials
55 drugs studied
Nabil Adra, MDIndiana University Melvin and Bren Simon Cancer Center3 years of reported clinical research
Studies Prostate Cancer
Studies Cancer
15 reported clinical trials
32 drugs studied
Shadia Jalal, MDIndiana University/Melvin and Bren Simon Cancer Center9 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
21 drugs studied
Greg DurmIndiana University/Melvin and Bren Simon Cancer Center4 years of reported clinical research
Studies Cancer
Studies Lung Cancer
7 reported clinical trials
14 drugs studied
Clinical Trials running at Sidney and Lois Eskenazi Hospital
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Fallopian Tube Cancer
Ovarian Cancer
Cancer
Laryngeal Cancer
Alzheimer's Disease
Peritoneal Cancer
Oropharyngeal Carcinoma
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This study is evaluating whether a combination of two drugs may help prevent breast cancer from coming back.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Sidney and Lois Eskenazi Hospital?
Sidney and Lois Eskenazi Hospital is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Breast Cancer, Human Immunodeficiency Virus Infection, Lung Cancer, Colorectal Cancer and other specialties. Sidney and Lois Eskenazi Hospital is involved with conducting 218 clinical trials across 410 conditions. There are 21 research doctors associated with this hospital, such as Kathy Miller, MD, Nabil Adra, MD, Shadia Jalal, MD, and Greg Durm.